A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01744808 |
Recruitment Status :
Completed
First Posted : December 7, 2012
Last Update Posted : April 3, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Normal, Healthy Volunteers | Drug: EB-1020 IR Drug: EB-1020 SR1 Drug: EB-1020 SR2 Drug: EB-1020 SR3 Other: Placebo | Phase 1 |
- To investigate the safety and tolerance of single doses of EB-1020 immediate release (IR) versus three sustained release (SR) formulations.
- To investigate the safety and tolerance of a single oral dose of a SR formulation of EB-1020 in the fed and fasted state.
- To investigate the safety, tolerance, and cognitive effects of multiple oral rising doses of a SR formulation of EB-1020.
Secondary Objectives
- To characterize the single dose and steady state pharmacokinetic profiles of EB-1020 SR formulations.
- To investigate the effect of food on the pharmacokinetic profile of EB-1020 SR following single oral doses.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 54 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Official Title: | A Phase 1 Study To Investigate the Pharmacokinetics of SR Formulations; and the Food Effect, Safety, Tolerance, Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020 In Young Healthy Subjects |
Study Start Date : | February 2013 |
Actual Primary Completion Date : | February 2014 |
Actual Study Completion Date : | February 2014 |
Arm | Intervention/treatment |
---|---|
Active Comparator: EB-1020 SR1
Sustained release formulation
|
Drug: EB-1020 SR1
sustained release |
Active Comparator: EB-1020 SR2
Sustained Release Formulation
|
Drug: EB-1020 SR2
Sustained release |
Active Comparator: EB-1020 SR3
Sustained Release Formulation
|
Drug: EB-1020 SR3
Sustained release |
Active Comparator: EB-1020 IR
Immediate Release Formulation
|
Drug: EB-1020 IR
Immediate release |
Placebo Comparator: Placebo
Placebo Formulation
|
Other: Placebo
Placebo formulation |
- Cmax [ Time Frame: up to 6 months ]Pharmacokinetic parameters
- Tmax [ Time Frame: up to 6 months ]Pharmacokinetic parameter
- AUC [ Time Frame: up to 6 months ]Pharmacokinetic parameter
- Effect of food on Cmax [ Time Frame: up to 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Aged 18-45 years inclusive
- Body weight with the normal range for height (body mass index [BMI] between 19-30 kg/m2 inclusive)
- If female, be of non-child bearing potential (surgically sterile, post-menopausal for 12 months or receiving a stable dose of implanted or injectable contraceptive for at least 3 months with last dose of injectable contraceptive within 2 months). Non-surgical menopause history must be confirmed by follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels as defined by established lab ranges.
- Be in general good health without clinically significant medical history
- Have clinical laboratory test results that are within the laboratory reference range; or if out of range are not clinically relevant and are acceptable to the Investigator and Sponsor medical representative
- Negative Human Immunodeficiency Virus (HIV), Hepatitis B and Hepatitis Screening test
- Able and willing to give written informed consent
Exclusion Criteria:
- Receipt of any investigational agent or drug within 3 months of entry into the study
- Use of prescription drugs within 4 weeks prior to first dosing. Subjects who have used over the counter medication excluding paracetamol, topical over the counter medications and routine vitamins but including megadose (intake of 20 to 600 times the recommended daily dose) vitamin therapy within 7 days of first dosing, unless agreed as non-clinically relevant by the Principal Investigator and Sponsor
- A history of, or current evidence for, suicidal ideation, based upon clinical interview and a psychiatric questionnaire
- A history of known or suspected seizures, spasms, infantile spasms, febrile convulsions, unexplained significant and recent loss of consciousness or history of significant head trauma with loss of consciousness or a family history (first degree relative) of epilepsy or seizures (fits)
- A history of sleep problems in the last 3 months
- A history of relevant atopy or drug hypersensitivity
- A history (within the last 5 years) or evidence of alcohol or drug abuse. Subject who consume more than 14 units (female) or 21 (male) units of alcohol a week (unit = 1 glass (125 mL) of wine = 1 measure of spirits = ½ pint of beer) will also be ineligible
- A positive urine test for drugs of abuse or alcohol at Screening or on the day of admittance to the Study Unit
- A history of smoking in the last 3 months
- Have a significant infection (such as influenza) or known inflammatory process on screening or admission
- Have acute gastrointestinal symptoms at the time of screening or admission (e.g. nausea, vomiting, diarrhea, heartburn )
- Have previously received EB-1020
- Be vegetarians, vegans or have medical dietary restrictions
- Any major surgical procedure within one month of entry into the study
- Have difficulties communicating reliably with the Investigator or appear unlikely to co-operate with the requirements of the study in the investigator's judgment.
- Any other condition which in the view of the Investigator is likely to interfere with study or put the subject at risk.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01744808
Australia, Victoria | |
Nucleus Network Ltd. | |
Melbourne, Victoria, Australia, 3004 |
Responsible Party: | Neurovance, Inc. |
ClinicalTrials.gov Identifier: | NCT01744808 |
Other Study ID Numbers: |
EB-1020-102 |
First Posted: | December 7, 2012 Key Record Dates |
Last Update Posted: | April 3, 2014 |
Last Verified: | April 2014 |
Healthy Normal |